Exercise of Warrants and Total Voting Rights

RNS Number : 2557J

Barkby Group PLC (The)

21 December 2020

 

The Barkby Group PLC

("Barkby", the "Group" or the "Company")

Exercise of Warrants and Total Voting Rights

The Barkby Group PLC, the diversified business group, announces that it has allotted 1,452,347 new ordinary shares of £0.00860675675675676 pence each in the capital of the Company ("Ordinary Shares") following the exercise of warrants by Giles Clarke.

Application has been made to the London Stock Exchange for the 1,452,347 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 24 December 2020.

After Admission, the total number of Ordinary Shares in issue will be 136,948,282 and the total number of voting rights will therefore be 136,948,282. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Enquiries: 

The Barkby Group PLC
Charles Dickson, Executive Chairman Douglas Benzie, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	[phone]
Carl Holmes/Simon Hicks (corporate finance) Tim Redfern/Richard Chambers (ECM)
Camarco (Financial PR)	[phone]

Jennifer Renwick/Jake Thomas

Notes to editors

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive.

In addition to these businesses, Barkby Life Sciences has invested in VivoPlex, a digital health company aiming to transform Women's Health with precision medicine, and its subsidiary Cambridge Sleep Sciences Ltd has launched, SleepHub™, a device which improves and facilitates natural sleep.

Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.

 

END

 

 

IOEUROURRSUUUUA